Adage Capital Partners
FPRX

Adage Capital Partners’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Adage Capital Partners’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-900,000
Closed -$15.3M – 1088
2020
Q4 		$15.3M Buy
+900,000
New +$11.3M 0.03% 494
2020
Q2 		– Sell
-250,000
Closed -$568K – 820
2020
Q1 		$568K Hold
250,000
– – ﹤0.01% 696
2019
Q4 		$1.15M Sell
250,000
-1,000,000
-80% -$3.96M ﹤0.01% 677
2019
Q3 		$4.84M Buy
1,250,000
+50,000
+4% +$274K 0.01% 630
2019
Q2 		$7.24M Buy
1,200,000
+50,000
+4% +$478K 0.02% 567
2019
Q1 		$15.4M Buy
1,150,000
+250,000
+28% +$2.85M 0.04% 444
2018
Q4 		$8.37M Buy
900,000
+252,000
+39% +$3M 0.02% 538
2018
Q3 		$9.02M Sell
648,000
-42,000
-6% -$625K 0.02% 561
2018
Q2 		$10.9M Sell
690,000
-110,000
-14% -$1.92M 0.03% 545
2018
Q1 		$13.7M Sell
800,000
-500,000
-38% -$9.75M 0.03% 492
2017
Q4 		$28.5M Sell
1,300,000
-1,132,700
-47% -$36.4M 0.06% 329
2017
Q3 		$99.5M Sell
2,432,700
-61,300
-2% -$1.92M 0.24% 110
2017
Q2 		$75.1M Sell
2,494,000
-96,000
-4% -$3M 0.18% 159
2017
Q1 		$93.6M Buy
2,590,000
+690,000
+36% +$30.4M 0.24% 117
2016
Q4 		$95.2M Sell
1,900,000
-225,100
-11% -$11.8M 0.26% 102
2016
Q3 		$112M Sell
2,125,100
-241,900
-10% -$11.6M 0.31% 85
2016
Q2 		$97.9M Sell
2,367,000
-233,000
-9% -$10.1M 0.27% 106
2016
Q1 		$106M Buy
2,600,000
+275,000
+12% +$9.45M 0.29% 98
2015
Q4 		$96.5M Sell
2,325,000
-339,949
-13% -$11.4M 0.25% 118
2015
Q3 		$41M Buy
2,664,949
+701,457
+36% +$15.1M 0.11% 231
2015
Q2 		$48.8M Buy
1,963,492
+350,208
+22% +$7.8M 0.12% 225
2015
Q1 		$36.9M Buy
1,613,284
+693,402
+75% +$17.5M 0.09% 285
2014
Q4 		$24.8M Buy
919,882
+419,882
+84% +$7.23M 0.06% 360
2014
Q3 		$5.87M Buy
500,000
+412,597
+472% +$5.21M 0.01% 600
2014
Q2 		$1.36M Buy
+87,403
New +$1.25M ﹤0.01% 666

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Adage Capital Partners's FPRX Position: Q1 2021 in Review

Adage Capital Partners sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2021, closing a stake of 900,000 shares — an estimated $15.3M sold.

Adage Capital Partners first reported a position in FPRX in Q2 2014 and held it in 25 quarters. The position peaked at $112M in Q3 2016. 147 funds tracked by Wall St. Rank hold FPRX as of Q1 2021.

  • Adage Capital Partners reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Adage Capital Partners sold 900,000 Five Prime Therapeutics, Inc. shares in Q1 2021, an estimated $15.3M.
  • Adage Capital Partners first reported a position in Five Prime Therapeutics, Inc. in Q2 2014 and held it in 25 quarters.
  • Adage Capital Partners's Five Prime Therapeutics, Inc. position peaked at $112M in Q3 2016.
  • 147 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2021.

Based on Adage Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.